Purposes: To study the clinical and genetic background of a series of Italian patients affected by Pattern Dystrophy (PD). Methods: We reviewed patients with a clinical diagnosis of PD examined at the Eye Clinic in Florence from 2012 to 2019. We took into consideration patients with a standard ophthalmological examination, personal and familial ophthalmological history, fundus imaging and molecular genetic analysis of genes PRPH2 and BEST1. We labelled patients with BEST1 and PRPH2 mutations as m-PD group (mutated) whereas patients with no mutations in these 2 genes as nm-PD group (non-mutated). Results: Seventy-seven PD patients were assessed (average age 59.7 14.2, range 31-88 yrs.). Fifty patients were placed in the nm-PD group and 27 in the m-PD. Pathogenic BEST1 and PRPH2 mutations were detected in 7% and 22% of PD patients respectively. In total, we reported 1 BEST1 and 8 PRPH2 novel mutations. Ten patients were characterized by drusen in the nm-PD group whereas in no patients in the m-PD group drusen were detected at the fundus. Conclusions: An important proportion of patients affected by PD showed BEST1 or PRPH2 mutations. Patients affected by drusen represent a different sub-phenotype. Genetic examination is recommended for a correct clinical management.
Clinical and molecular findings in patients with Pattern Dystrophy / Sodi Andrea, Mucciolo Dario Pasquale, Giorgio Dario, Passerini Ilaria, Pacini Bianca, Bruschi Mario, Verdina Tommaso, Virgili Gianni, Giansanti Fabrizio, Murro Vittoria. - In: OPHTHALMIC GENETICS. - ISSN 1381-6810. - ELETTRONICO. - (2021), pp. 1-10. [10.1080/13816810.2021.1938140]
Clinical and molecular findings in patients with Pattern Dystrophy
Sodi Andrea;Mucciolo Dario Pasquale
;Giorgio Dario;Passerini Ilaria;Pacini Bianca;Bruschi Mario;Virgili Gianni;Giansanti Fabrizio;Murro Vittoria
2021
Abstract
Purposes: To study the clinical and genetic background of a series of Italian patients affected by Pattern Dystrophy (PD). Methods: We reviewed patients with a clinical diagnosis of PD examined at the Eye Clinic in Florence from 2012 to 2019. We took into consideration patients with a standard ophthalmological examination, personal and familial ophthalmological history, fundus imaging and molecular genetic analysis of genes PRPH2 and BEST1. We labelled patients with BEST1 and PRPH2 mutations as m-PD group (mutated) whereas patients with no mutations in these 2 genes as nm-PD group (non-mutated). Results: Seventy-seven PD patients were assessed (average age 59.7 14.2, range 31-88 yrs.). Fifty patients were placed in the nm-PD group and 27 in the m-PD. Pathogenic BEST1 and PRPH2 mutations were detected in 7% and 22% of PD patients respectively. In total, we reported 1 BEST1 and 8 PRPH2 novel mutations. Ten patients were characterized by drusen in the nm-PD group whereas in no patients in the m-PD group drusen were detected at the fundus. Conclusions: An important proportion of patients affected by PD showed BEST1 or PRPH2 mutations. Patients affected by drusen represent a different sub-phenotype. Genetic examination is recommended for a correct clinical management.File | Dimensione | Formato | |
---|---|---|---|
13816810.2021.1938140_compressed.pdf
Accesso chiuso
Tipologia:
Pdf editoriale (Version of record)
Licenza:
Tutti i diritti riservati
Dimensione
4.71 MB
Formato
Adobe PDF
|
4.71 MB | Adobe PDF | Richiedi una copia |
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.